Catalyst Pharmaceuticals Inc.

# Signal Note: Deerfield Initiates Major CPRX Position Deerfield's $114.6M entry into Catalyst (4.9M shares, ~7-8% of float) signals conviction in the company's rare disease portfolio, likely anchored on Firdapse (amifampridine) for Lambert-Eaton myasthenic syndrome and recent pipeline expansion. The timing suggests confidence in near-term catalysts, potentially including label expansion data, reimbursement wins, or M&A optionality given Catalyst's relatively small market cap (~$1.5B) and Deerfield's history of value-creation through operational improvements in specialty pharma.